

The Texas Heart Institute at Baylor College of Medicine Cardiology Grand Rounds

Friday, February 27, 2026
12:00 – 1:00 p.m.

Current and Future Directions in Prevention and Treatment of Cardiometabolic Disease

Christie M. Ballantyne, MD, FACP, FACC

Section Chief, Cardiology and Cardiovascular Research
Professor, Medicine, Molecular and Human Genetics, and
Molecular Physiology and Biophysics

J. S. Abercrombie Chair:

Atherosclerosis and Lipoprotein Research

Director, The Maria and Alando J. Ballantyne, M.D.

Atherosclerosis Clinical Research Laboratory

Director, Center for Cardiometabolic Disease Prevention

Co-Director, Lipid Metabolism and Atherosclerosis Clinic

Baylor College of Medicine



In-Person Location

Baylor St. Luke's Medical Center

Denton A. Cooley Auditorium (C060, Level B1)

6720 Bertner Avenue

Microsoft Teams Access and Attendance Process

- ▶ Click here to join the presentation: <https://forms.office.com/r/mH7KKfQ9Jv>
- ▶ [Sign in to track attendance and earn credit.](#)
Text Phone Number: **713-903-7277**
Event ID: **DUXGUR**

Objectives: At the conclusion of the session, the participants should be able to:

- Compare technologies and administration routes of PCSK9 inhibitors.
- Summarize recent trials of apo C-III inhibition in patients with hypertriglyceridemia.
- Discuss cardiovascular benefits of antiobesity drugs.

Target Audience: This activity is intended for cardiologists, cardiovascular and cardiothoracic surgeons, anesthesiologists, intensivists, primary care physicians, fellows, residents, medical students, physician assistants, nurses, nurse practitioners, other advanced practice providers, and perfusionists at Baylor St. Luke's Medical Center, Baylor College of Medicine, and the greater Texas Medical Center.

Needs Statement: Clinicians engaged in the practice of cardiovascular medicine including physicians in practice, faculty members, fellows, residents, medical students, allied health and other healthcare practitioners and care team members in related disciplines need to receive regular updates on evidence-based clinical practices, and technological and pharmaceutical advances in cardiovascular medicine. The series aims to expand the knowledge of learners, advance their clinical skills and competencies, address the challenges of healthcare delivery in the clinic, hospital, diagnostic, and surgical settings to enhance the quality of cardiovascular care, and improve patient outcomes by providing education to address gaps arising from the continually evolving practice standards, how to implement them, and the steps for performance change.

Educational Methods: Educational methods will include lectures, case presentations, and audience response.

Activity Evaluation: Participants may be asked to complete a session evaluation.

Accreditation/Credit Designation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Baylor College of Medicine and The Texas Heart Institute. Baylor College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

Relevant Financial Relationships with Ineligible Companies: *All relevant financial relationships listed have been mitigated.*

Christie M. Ballantyne, MD, FACP, FACC	Presenter
Research Support (All Financial Relationships Are Current): Abbott Diagnostic, Akcea, Amgen, Arrowhead, Eli Lilly, Ionis, Merck, New Amsterdam, Novartis, Novo Nordisk. Consultant (All Current): 89Bio, Abbott Diagnostics, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Genentech, HeartFlow, Ionis, Eli Lilly, Merck, New Amsterdam, Novartis, Novo Nordisk, Roche Diagnostic; Advisory Committee (All Current): Eli Lilly, Merck, New Amsterdam BSCI, Medtronic, Siemens, Truleaf Medical, WL Gore.	

No Financial Relationships with Ineligible Companies: *Nothing to disclose.*

Select all roles that apply for this session.

Karla Campos Bekardi, MD	<input checked="" type="checkbox"/> Planning Committee Member	<input type="checkbox"/> Presenter	<input type="checkbox"/> Moderator	<input type="checkbox"/> Panel Discussant
Stephanie Coulter, MD	<input checked="" type="checkbox"/> Planning Committee Member	<input type="checkbox"/> Presenter	<input type="checkbox"/> Moderator	<input type="checkbox"/> Panel Discussant
Pakinam Mekki, MD	<input checked="" type="checkbox"/> Planning Committee Member	<input type="checkbox"/> Presenter	<input type="checkbox"/> Moderator	<input type="checkbox"/> Panel Discussant
Joseph G. Rogers, MD	<input checked="" type="checkbox"/> Planning Committee Member	<input type="checkbox"/> Presenter	<input type="checkbox"/> Moderator	<input type="checkbox"/> Panel Discussant

CONFIDENTIALITY ACKNOWLEDGEMENT

This regularly scheduled series (RSS), planned by/presented to the institution's professional staff, is accredited by Baylor College of Medicine (BCM) for *AMA PRA Category 1 Credit™* for physicians. In connection with my participation in this RSS, I understand that I may be exposed to patient information, research participant information, and/or proprietary information (collectively referred to as "Confidential Information"). I agree to keep this information confidential and not to disclose the information to any other person or entity unless in accordance with applicable federal and state laws and the policies and procedures of BCM and/or its affiliated entities.